Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

Summary

The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers"). 60% of participants will receive Niagen and 40% will receive PBO. Outcomes will consist of standardized cognitive, neuropsychiatric, physical, functional and biomarker assessments.

Timeline

Start

2021-08-28

Primary completion

2023-10-05

Completion

2024-02-23

Publications

• Wu CY, Reynolds WC, Abril I, McManus AJ, Brenner C, Gonzalez-Irizarry G, Gutierrez-Martinez L, Sun O, Rosand J, Tanzi RE, Arnold SE, Guzman-Velez E. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. 2025 Nov 12;89:103633. doi: 10.1016/j.eclinm.2025.103633. eCollection 2025 Nov.

Drugs

Indications